K-Beauty Leaders Amorepacific and APR Pivot Toward Energy-Based Medical Device Market

Major K-beauty players Amorepacific and APR are aggressively expanding into the energy-based device (EBD) sector, targeting professional medical aesthetic markets beyond traditional home-use beauty tools. This shift toward high-value-added medical technology includes the development and distribution of radiofrequency, laser, and ultrasound equipment for clinical use. The move is significant for the medical device sector as it introduces well-capitalized consumer brands into the B2B aesthetic space, potentially reshaping the competitive landscape for established medical device manufacturers.

Amorepacific and APR are transitioning from cosmetic-focused business models to becoming "beauty-tech" entities by entering the energy-based device (EBD) market for hospitals and clinics. EBD technology encompasses medical devices using lasers, radiofrequency (RF), high-intensity focused ultrasound (HIFU), and microneedle RF for procedures such as skin lifting and pigmentation treatment. This strategic pivot is driven by the high profitability of the medical device sector, where equipment can cost hundreds of millions of won and generates recurring revenue through the sale of consumables like specialized tips and cartridges.

The two companies are pursuing distinct entry strategies: Amorepacific is focusing on strategic investments and partnerships, while APR is opting for full internal development. Amorepacific Holdings recently signed an investment agreement with Higher Corporation, the developer of the "HiloWave" collagen booster, following a previous investment in microneedle RF specialist ViOL Medical. Conversely, APR is leveraging its R&D and manufacturing experience from its Medicube AGE-R home device line to independently develop and mass-produce professional-grade EBD equipment, with a market entry targeted for late 2024 or early 2025.

The expansion into medical aesthetics reflects a broader global trend, exemplified by L'Oréal’s recent stake in dermatology specialist Galderma. For the medical device industry, this influx of capital and brand power from the cosmetics sector signals a shift in corporate valuations, as technology-driven medical device firms typically command higher margins than traditional beauty brands. However, these new entrants must still navigate rigorous international regulatory approvals and compete with established medical device incumbents like Classys, Hugel, and Pharmaresearch, which already possess extensive clinical data and established sales networks in dermatology clinics.